These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 23356214)

  • 1. Targeted therapies in colorectal cancer-an integrative view by PPPM.
    Hagan S; Orr MC; Doyle B
    EPMA J; 2013 Jan; 4(1):3. PubMed ID: 23356214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
    Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
    Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
    Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
    Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
    Mármol I; Sánchez-de-Diego C; Pradilla Dieste A; Cerrada E; Rodriguez Yoldi MJ
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
    Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
    Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.
    Barton S; Starling N; Swanton C
    Curr Cancer Drug Targets; 2010 Dec; 10(8):799-812. PubMed ID: 20718710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
    Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
    J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.
    Gupta K; Jones JC; Farias VA; Mackeyev Y; Singh PK; Quiñones-Hinojosa A; Krishnan S
    Front Oncol; 2022; 12():840241. PubMed ID: 35664781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
    Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A
    Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized treatment for advanced colorectal cancer: KRAS and beyond.
    Patel GS; Karapetis CS
    Cancer Manag Res; 2013; 5():387-400. PubMed ID: 24294007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.